Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A little DD on the patent process.
During prosecution of a US patent application, a second or subsequent Office Action can be made final by the examiner. “Final” is a misnomer, however, because a final rejection does not mean that prosecution of the patent application is over. In fact, there are several procedural options available to a patent applicant after receiving a final rejection.
A first option is to file a Request for Continued Examination (RCE). An RCE reopens prosecution and causes the examiner to take another look at the application based on amendments or arguments in a Preliminary Amendment submitted with the RCE. While an RCE and Preliminary Amendment may be a good strategic option in many circumstances, it can be an expensive one: the US Patent & Trademark Office (USPTO) charges large entities a fee of $1,200 for a first RCE filed in an application and $1,700 for a second or subsequent RCE in that application. These fees are discounted 50% for small entities and 75% for micro entities.
A second option is to file an Amendment After Final (AAF). AAFs do not require any USPTO fees, but examiners are given a limited amount of time to consider them. Therefore, they can be most effective when straightforward arguments or amendments can be presented to overcome rejections or when the remaining issues are relatively simple (e.g., claim amendments as to form in order to resolve rejections under 35 U.S.C. § 112).
A relatively new option in US after-final practice is the After Final Consideration Pilot 2.0 (AFCP) program. An AFCP request can be filed with an AAF and gives an examiner some additional, though still limited, time to consider the AAF. In order to file an AFCP request, the application must be finally rejected, an AAF must be filed, and the AAF must include an amendment to at least one independent claim, with that amendment not broadening the claim in any way. The applicant or its representative must also agree to be available for a telephone interview with the examiner. Though interviews are not always held as part of the AFCP program, they can be very helpful for better understanding the issues and the examiner’s current position in the case.
If an AAF is not successful at resolving the remaining issues, the examiner will issue an Advisory Action. Advisory Actions sometimes include only basic information (e.g., the examiner considers the AAF to raise new issues requiring further search and/or consideration, such that the application is not in condition for allowance), though oftentimes the examiner will include some additional information about their review of the AAF or any prior art they think might apply, whether new or already on the record.
Though there are several options available at this point, including abandoning the application with or without filing a new continuation application, it is common to file an RCE and Preliminary Amendment in order to reopen and continue prosecution.
Another option after receiving a final rejection—or following an Advisory Action if an AAF was filed—is to file an appeal. An appeal is initiated by filing a Notice of Appeal and eventually sends the application for review by the USPTO’s Patent Trial & Appeal Board (PTAB). It can be a time-consuming endeavor, with most appealed applications waiting in queue for two years or more before being considered by the PTAB. It is also more expensive than the other options, requiring at least $2,800 in USPTO fees.
An optional step in the appeal process is filing a Pre-Appeal Brief Request for Review with the Notice of Appeal. This pre-appeal process does not require any USPTO fees and is requested by filing a five-page brief of the issues. The brief is then considered by a panel of three examiners, one of whom is the examiner primarily responsible for the application, and the panel can either send the application back to the examiner for further prosecution, allow it to continue in the appeal process, or pass the application to allowance. This third scenario is unusual, with most applications continuing to appeal or being sent back to the examiner.
The time and costs for these and other after-final options can vary widely, and the most appropriate option in any case can depend on a variety of different circumstances. Therefore, if you receive a final rejection, know that the rejection does not mean that the end of prosecution, and discuss the available options with your attorney in order to determine the best strategic option.
Thanks. I guess my confusion was OTC isn't considered publically listed. I don't recall seeing anything about an "IPO" when Chronos, a Canadian stock listed OTC moved to the NASDAQ. f
Looks like many are missing that. The S1 isn't an "IPO" since nFuszis already public and it isn't the application to uplist to NASDAQ, but it is share dilution of about 40 million shares. It may help get us listed on NASDAQ (I hope so), but maybe it doesn't and the price continues to drift lower until financials start to drive the price.
From the S1:
"We intend to apply to list our Common Stock on the Nasdaq Capital Market (“NASDAQ”) under the symbol “FUSZ,” which listing we anticipate will occur simultaneously with the closing of this offering. We have not yet received approval to list our Common Stock on NASDAQ and there is no assurance that our Common Stock will ever be listed on NASDAQ."
So this is the S1 for the public offering of up to $20 mil in shares?
Only filings I see for 8/14/18 are the 10Q and the S1.
I think we'll see .25 before we see 2.50. I'm down 80%, but staying at this point. SHAC's are great, but until we actually see some of the promises coming to fruition and having a bigger impact on the bottom line I don't think we're going to see much upward movement. IMO
Unless I’m reading it wrong the Form 4 dated 8/10/18shows Rory acquired 2;447;600 shares via warrant at .49 a share on 8/8/18.
Or just plain day trading?
So is this what the "Market Maker" activity looks like? You've got ASCM buying at .0048 and selling at .0069, CTSI buying at .0055 and selling at .0056, CDEL buying at .0055 and selling at .0056, ERTF buying at .0055 and selling at .0057, etc.
Agreed. All sales are good news.
That's the way I read it at first, but then further down in mentions "The show is attended each year by 45,000 buyers from over 90 countries. Of those attendees, 98% have major purchasing power such that the average buyer spends $82,500 per show...". So this makes me a bit of a doubter since if the 400 were orders and each order was worth even half that amount it would equate to $16 million. That would be awesome, but I doubt it.
News is why it will keep dropping, $5 million loan to cover bills so vendors will keep processing payments. This will be back to .25 by the end of next week if not sooner.
I used to have the POTN ads when logged in, but yesterday started getting Pacific Rim Cobalt. POTN ads are still there if I'm not logged in though.
So glad I sold out at the end of June for a small loss at .268 after hearing R/S talk. Circling the drain and probably bankrupt by end of the year
Here's what I hate about reverse splits. For every 1000 shares I own I see $1000 potential profit for if the stock prices increases by $1. However, after a 1:10 split I now only see a $100 improvement. From what I've seen stocks that do a reverse split never seem to rise as fast as they were prior to the split.
Alpert - that’s exactly what I’m questioning
Could be, the only surgery I’ve had was to remove a pterygium from one of my eyes. He did the procedure at a local surgical center and I was charged for the consultation in his office prior, the actual surgery and the office visit to see how I was healing after I went through radiation treatment to minimize the risk of recurrence. So I guess it depends on the procedure.
I agree and you’re correct they do make more on new patient visits, but many of the follow-up appointments won’t be able to be addressed without an interaction with the Dr or at least a nurse practitioner. Treatment progress to determine next steps and possibly new prescriptions are two that come to mind right off. Sure they can deliver test results, but most already have an online process for that
I agree. Until some meaningful PRs and/or positive financial results this will continue to slide lower. I’ll just continue to hold what I’ve got.
Only part of the SHAC I really question was the part on NotifyMD freeing up calendars of follow-up appointments doctors don’t get paid for?? My wife has been doing the billing for multiple practices over the past 30 years and doctors get paid for each visit. There are even different payable codes for the type and length of visit, but they get paid. NotifyMD may help in other ways, but I don’t think freeing up unpaid follow-up visits is one of them, unless their billing staff doesn’t know what they are doing.
Supposed to be a vote in August right? Vote NO
Bummed out Fidelity won't allow trades on this because of the Stop Sign on OTC Markets. Tried to get in when it was at .0005.
Depends on the company being bought and their potential upside.
I think Hiku could have easily doubled by the end of the year and maybe higher into 2019. So say I had 1000 shares of Hiku and when news was released the price was $1.13. If the value doubled my share value would increase from $1130 to $2260. Canopy is giving me .046 shares for every Hiku share so I would have 46 shares of Canopy which was at $29 when news came out, or a value of $1334. Granted this is better than the current $1130 value of my Hiku shares, but to get to the same $2260 if Hiku would have increased to $1.13 my 46 Canopy shares would have to see over a $20 increase to $49.13.
Got in at the wrong time. I believe in the technology, but I'm down 70% and definitely won't be throwing anymore money at this until I see some decent signs of recovery
That site works. Talking about uplisting right now.. paperwork almost complete then 30-60 day waiting period. Expect to have it done before end of the year.
Not quite. Definitely closer to legalization.
"MPs there will now have to decide what to do about the almost four dozen amendments to Bill C-45 that were made in the Senate.The government will have to decide whether to approve, reject or modify the changes before returning the bill back to the Senate for another vote."
Patience until the vote is over and legalization approved. Without legalization not worth the current valuation
Got in under $2 and saw some of the rise through April. Added shares at just under $1 and again at .74 but done “buying the dip”. This is on an express elevator to the basement and as much as I hate to say it we’ll probably see sp < .10 before we see $1 again. Still believe in what I’ve seen so not selling but definitely not throwing any more more money at this until I see multiple days in the green
Any proof of this noteholder dilution? Easy to research the short interest which was over 36% of trading volume on May 8th.
https://www.otcshortreport.com/company/POTN
No shorting pennies? Can you explain why OTC Short Report shows naked shorting of POTN then? 47% of volume on May 7th was naked shorts.
https://www.otcshortreport.com/company/POTN
Came to ask same question. Fidelity hasn't show the chart since the Stop came up on OTCMarkets, but at least you could see the daily gain/loss. Hasn't shown anything today.
Possibly due to a negative comment from the accountant in their 2017 annual report.
https://www.fool.com/investing/2018/05/01/this-marijuana-producer-just-got-slapped-in-the-fa.aspx
I'm hoping the same, new week better results. GLTU as well.
It very well may be the best thing since sliced bread, but it's also true that many cutting edge ideas/products fail, sometimes more than once before they come to fruition. I'd love to see this thing take off, but you'd think if it was that good, especially with the conference and potential new investors we could break even at least one day over the last week or so.
Yeah I have to decide if I'm going to cut my losses. Got in in the in the low-mid 2's and down about 50% now. If it wasn't consecutive day losses maybe, but this seems to be on a freight train to the cellar. Maybe sell out and buy back in when if/when it gets to the .60-70 range.
I think it's assumption. I couldn't find anything either but 8K from early January says application should be developed within 120 days, but sounds like integration my not be until later this year.
"The Agreement provides that the development of the application, which will be undertaken jointly by us and ORACLE, will be completed within one year. We anticipate that development of the application, which has already begun, will be completed within 120 days"
June 2017 article BELOW said MJNA owns 43% of AXIM and according to MJNA website they own approximately 45.5% of AXIM
https://www.fool.com/investing/2017/06/09/better-know-a-marijuana-stock-axim-biotechnologies.aspx
Was looking at PHVAF today, interested until I saw Ask price was running .30-.40 above current price. I’ll admit I’ve only been investing about 2 years but first time I’ve seen that big of a difference, Hard for me to take a position where I immediately need to see a 30% increase just to break even. What gives? Joined iHub just to ask this ?